Aerie Pharmaceuticals has completed enrollment in a phase 2 clinical trial of netarsudil ophthalmic solution in Japan, according to a press release.
The prospective, double-masked, multicenter, placebo-controlled, parallel group trial includes 215 patients randomly assigned to one of four treatment arms: netarsudil 0.01%, 0.02% or 0.04% or placebo, administered once daily in the evening.
“We believe this rapid enrollment reflects the enthusiasm of the clinical investigators at the 25 centers across Japan that participated in the study and is a credit to our clinical operations teams in
Uncategorized